NeuroSense Therapeutics Shareholders Approve All Resolutions
Ticker: NRSNW · Form: 6-K · Filed: Jul 3, 2024 · CIK: 1875091
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing-update
TL;DR
NeuroSense shareholders voted YES on everything at the June 27th meeting.
AI Summary
NeuroSense Therapeutics Ltd. held its Annual General Meeting of Shareholders on June 27, 2024. All resolutions presented to the shareholders, which were previously detailed in the company's May 28, 2024, Form 6-K filing, were approved.
Why It Matters
Shareholder approval of all resolutions is a routine but necessary step for corporate governance, indicating continued support for the company's management and strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine report of a shareholder meeting where all proposed resolutions were approved, indicating no new or significant risks.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the report
- June 27, 2024 (date) — Date of the Annual General Meeting of Shareholders
- May 28, 2024 (date) — Date of the previous Form 6-K filing detailing resolutions
FAQ
What was the purpose of the Form 6-K filing?
The Form 6-K filing reports on the outcome of NeuroSense Therapeutics Ltd.'s Annual General Meeting of Shareholders held on June 27, 2024, confirming that all proposed resolutions were approved.
When was NeuroSense Therapeutics Ltd.'s Annual General Meeting of Shareholders?
The Annual General Meeting of Shareholders was held on June 27, 2024.
Were the resolutions presented at the meeting approved?
Yes, all proposed resolutions presented at the Annual General Meeting of Shareholders on June 27, 2024, were approved by shareholders.
Where can shareholders find details about the resolutions that were voted on?
Details about the resolutions were provided in the Company's Notice and Proxy Statement furnished on Form 6-K to the Securities and Exchange Commission on May 28, 2024.
Does NeuroSense Therapeutics file annual reports under Form 20-F or 40-F?
NeuroSense Therapeutics Ltd. indicates that it files annual reports under Form 20-F.
Filing Stats: 256 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-07-03 09:11:02
Filing Documents
- ea0208944-6k_neurosense.htm (6-K) — 10KB
- 0001213900-24-058810.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: July 3, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2